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Introduction
Colorectal cancer (CRC) occurs mainly in elderly patients. Recent European evaluation reported that 38.5% of CRC patients were over 75 (1) . Several concerns have risen about the care of elderly due to the age-related comorbidities and functional status (2) . Moreover, elderly patients are underrepresented in clinical trials, thus the transposition for elderly of current guidelines established in younger patients should be taken with caution (3; 4).
In first line metastatic CRC (mCRC), bevacizumab combined with irinotecan has demonstrated an overall survival (OS) advantage compare to irinotecan based chemotherapy alone (5) and an improvement of progression-free survival (PFS) in combination with 5-fluorouracil (FU) compare to single FU regimen in patients considered unfit for a doublet chemotherapy regimen (6) .
Two recent phase III trials comparing capecitabine alone or combined with bevacizumab have focused on elderly patients. Both studies reported a PFS improvement in the bevacizumab arm (7; 8) without significant OS improvement.
Some concerns also raised for the use of usual oncologic endpoints as OS and PFS in elderly patients (9) . It has been reported that if elderly patients have a good acceptance of chemotherapy they are less willing to have a toxicity than their younger counterparts (10) . Moreover, unplanned hospitalization is a concern in elderly patients as it can delay scheduled treatment and result in functional decline (11) . A recent guideline of the International Society of Geriatric Oncology (SIOG) recommends to the use of composite endpoint evaluating quality of life (QoL) and global toxicity for mCRC trials in elderly (12) . According to these recommendations we built specifically for PRODIGE 20 trial a composite endpoint assessing efficacy Several studies have demonstrated that doublet chemotherapy have a limited effect on PFS and did not prolong OS compare to fluoropyrimidine alone in elderly patients (13; 14) . Nevertheless, the SIOG guideline recommends doublet chemotherapy in fit elderly patients (12) . Thus, it is important to allow chemotherapy choice according to investigator evaluation.
Patients and Methods

Patient selection
The eligibility criteria were histologically confirmed unresectable mCRC, age ≥75 
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20% of the patients (40% expected) and a safety co-criterion for more than 40% of the patients (70% expected), 92 evaluable patients was needed (one-sided alpha=5%, power=90%). All patients with a mCRC, receiving at least one dose of treatment and with at least one efficacy assessment and one Spitzer evaluation after treatment, were considered evaluable and included in the modified intent-to-treat population (mITT). Assuming for 10% non-evaluable patients, 102 patients were randomized in the trial. The decision rules applied only for BEV arm were: if ≥15
patients met the efficacy co-criterion and if ≥25 patients met the safety co-criterion, the treatment was considered efficient and well tolerated.
Secondary endpoints
Secondary endpoints were objective tumor response rate (ORR), PFS, OS, and tolerance. ORR was defined as complete or partial response. PFS was defined as the time from randomization to first progression or death (all causes). Patients alive without progression were censored at the last follow-up. OS was defined as the time between randomization and death (all causes). Toxicity was reported by the maximum toxicity grade per patient and per toxicity term during the treatment.
Results
Baseline characteristics
Between July 2011 and July 2013, 51 patients were randomly assigned to CT and 51
to BEV (figure 1). The median follow-up was of 20.4 (Q1-Q3: 11. 
Treatment administration
The median duration of the treatment was 6.0 months (Q1-Q3: 3.3-9.9) in CT and 7. table S1 ).
Primary composite co-criterion
According to the decisions rules, both efficacy and safety objectives for BEV were 
Prediction of PFS and OS by both and combined composite co-criterion
An exploratory analysis was performed to assess the predictive value of both and combined composite co-criterion for PFS and OS (supplementary table S4 ). Efficacy, safety and combined composite co-criterion were associated with PFS and OS.
Tolerance
The main severe adverse events (grade 3-4) in CT and BEV arm were respectively neutropenia (12.2% versus 11.8%), diarrhea (10.2% versus 9.8%), and thromboembolic events (6.1% versus 9.8%). As expected with bevacizumab, Grade 
Discussion
This randomized study was the first one evaluating bevacizumab treatment in mCRC patients aged of 75 or more according to geriatric guidelines. Our results
showed that the addition of bevacizumab to chemotherapy was safe and efficient.
This randomized phase II study was non comparative so not designed to demonstrate any difference or superiority of BEV arm over the CT arm for primary or secondary endpoints.
The efficacy co-criterion assessed 4 months after the randomization was reached in BEV. The separate analysis of the 2 efficacy criteria considered showed that the tumor control rate was higher in BEV arm but the QoL was less deteriorated in the CT arm. The trend observed in favor of CT for QoL could be explained by the slight difference existing in term of safety meaning that QoL and toxicities are correlated. The time to QoL degradation was similar in both arms (16) .
Concerning the safety part, the majority of the patients had no unexpected hospitalization and there is few severe cardiovascular toxicity in both arms during the first 4 months. Considering all toxicities during the treatment duration there is an 
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increased of arterial hypertension and a 3.7% difference for thrombolytic events as expected with bevacizumab. This is in-line with what it was observed in previous study in elderly (7; 17) . A careful monitoring of anti-hypertensive treatment is needed in elderly treated with bevacizumab.
Composite co-criterion assessing both tumor control, QoL and tolerance remains exploratory. The tumor control rate was in the same range for CT that those observed in our previous trial comparing 5-fluorouracil monotherapy to FOLFIRI (13) .
The prognostic value of Spitzer QoL score have been validate in oncology setting (18) . Because of the lack of previous prospective data about the evolution of Spitzer
QoL score under treatment in elderly patient treated for mCRC the hypothesis used in our trial design was exploratory. The optimal time of evaluation is also questionable as treatments are both well-tolerated. Unfortunately, QoL evaluations are exposed to a high drop-out rate. Around 10% of the patients in our study didn't have an evaluation at 4 months and this rate increased afterwards. Indeed, an intensive monitoring and investigators training is mandatory if QoL is part of primary endpoint. The safety co-criterion appears as poorly discriminant between both arms.
Nevertheless, both criteria are predictive for PFS and OS but this observation is obtain on small number. It must be point out that our criteria was built specially to evaluate anti-angiogenic toxicity and could not be used for other purpose. Further research for optimal composite criteria is needed in geriatric oncology.
Our PFS results are in favor of BEV but are of less magnitude compared to the results of the two previous studies that have compared bevacizumab plus capecitabine to capecitabine monotherapy (HR= 0.53 (7) and 0.52 (8)). It must be pointed out that the median age was 80 years in our study but 76 (7) and 78 (8) None previous study demonstrated a significant OS benefit of bevacizumab combined with chemotherapy compared to chemotherapy alone in elderly patients.
Our OS results are consistent with previous observations in phase III randomized study that have addressed elderly patients (7; 8).
It must be pointed out that there is a trend in favor of BEV for usual endpoint as PFS and OS. At the contrary, QoL, unexpected hospitalization, cardiovascular toxicity and in result the primary safety co-criterion seems to be in favor of CT. This observation suggests that bevacizumab was associated with more toxicity even mild but is worthwhile given the longer PFS and OS.
We evaluated bevacizumab both in combination with FU monotherapy or with doublet chemotherapy which was never evaluated in previous randomized studies (7; 8). The investigators were allowed to choose between monotherapy or doublet according their evaluation of the patient. This pragmatic design minimize patient selection to enter the trial. Moreover, around 50% of patients received FU monotherapy or doublet, this proportion is close to those observed in a national cohort of elderly patient treated in front line for mCRC in France (21) . Nevertheless, we could not rule out a part of patient selection for enter in a clinical trial. In our study, the effect of bevacizumab was similar whatever the doublet regimen delivered. It must be point out that doublet chemotherapy was not associated with an increase of PFS or OS in subgroup analyses that raise the question of the need for doublet therapy in front line (16) . Nevertheless, our results confirm the possibility to combine bevacizumab with several chemotherapy regimens in elderly patients. 
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In our study, we observed a prolonged median duration of exposure to treatment despite advanced age. This could be explained by the pragmatic design of the trial that allow a tailored chemotherapy according to the investigator evaluation of the patient. Alternatively we can't rule out a more stringent patient selection than in the previous trial that have evaluated bevacizumab in elderly (7; 8) . Moreover, 55%
of patients received a second-line therapy compared to 37% in the AVEX trial (7) and 10% in AGITG MAX trial (8) . This high proportion of second-line treatment especially in the CT group could explain that the OS are close in both groups. It must be pointed out that more than 40% of patients were treated with a targeted therapy in second line in CT versus 25% in BEV.
In conclusion, bevacizumab in combination with both 5-fluorouracil monotherapy or doublet chemotherapy is well-tolerated and efficient in selected elderly patients. A trend for a longer tumor control is observed in BEV compare to CT. A phase III trial or with endpoint adapted to geriatric population would be of interest.
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